In summary, our results identify immune-mediated pathways in myeloid cells and in particular monocyte/macrophage derived NF-κB as a potential target for therapeutic interventions in the treatment of autoimmune diseases such as MS. Here, NFKB1 is linked to myeloid sarcoma.